📊 KZR Key Takeaways
Is KZR a Good Investment? Thesis Analysis
Kezar Life Sciences presents a paradoxical fundamental profile: exceptional financial health with $71.9M cash, zero debt, and improving operational losses, yet faces acute execution risk as a pre-revenue pharmaceutical company with ~16 months of runway at current burn rates. The solid balance sheet provides strategic flexibility, but the outcome depends entirely on clinical trial success and FDA approvals rather than operational fundamentals.
Why Buy KZR? Key Strengths
- Exceptional liquidity with $71.9M cash reserve against only $6.6M liabilities, providing substantial operational flexibility
- Zero debt and minimal capital requirements reduce refinancing risk and preserve strategic options
- Operating losses improving 33.1% year-over-year, suggesting operational discipline or progress toward clinical milestones
- Strong stockholders equity of $70.1M relative to asset base indicates clean balance sheet
KZR Investment Risks to Consider
- Pre-revenue status with zero commercial traction creates binary outcome dependency on unproven pipeline
- Annual cash burn of $51.8M against reserves yields only ~16 months runway, requiring near-term capital raise
- Existential clinical and regulatory risk - all enterprise value depends on FDA approvals for experimental drugs
- Shareholder dilution likely from future equity financing rounds needed before profitability
- No disclosed insider buying activity in 90 days, suggesting limited management conviction at current burn trajectory
Key Metrics to Watch
- Quarterly cash burn trend and updated runway - early indicator of financing urgency
- Clinical trial enrollment, efficacy data releases, and FDA milestone announcements for pipeline programs
- Partnership announcements or licensing deals indicating external validation of asset value
KZR Financial Metrics
💡 AI Analyst Insight
Strong liquidity with a 11.52x current ratio provides a solid financial cushion.
KZR Profitability Ratios
KZR vs Healthcare Sector
How Kezar Life Sciences, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is KZR Overvalued or Undervalued?
Based on fundamental analysis, Kezar Life Sciences, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
KZR Balance Sheet & Liquidity
KZR 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: Kezar Life Sciences, Inc.'s revenue has remained relatively flat over the 5-year period, with a 0% decline. The most recent EPS of $-14.04 indicates the company is currently unprofitable.
KZR Growth Metrics (YoY)
KZR Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | N/A | -$20.3M | $-2.78 |
| Q3 2023 | N/A | -$16.0M | $-0.25 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
KZR Capital Allocation
KZR SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for Kezar Life Sciences, Inc. (CIK: 0001645666)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KZR
What is the AI rating for KZR?
Kezar Life Sciences, Inc. (KZR) has an AI rating of HOLD with 68% confidence, based on fundamental analysis of SEC EDGAR filings.
What are KZR's key strengths?
Claude: Exceptional liquidity with $71.9M cash reserve against only $6.6M liabilities, providing substantial operational flexibility. Zero debt and minimal capital requirements reduce refinancing risk and preserve strategic options.
What are the risks of investing in KZR?
Claude: Pre-revenue status with zero commercial traction creates binary outcome dependency on unproven pipeline. Annual cash burn of $51.8M against reserves yields only ~16 months runway, requiring near-term capital raise.
What is KZR's revenue and growth?
Kezar Life Sciences, Inc. reported revenue of $0.0.
Does KZR pay dividends?
Kezar Life Sciences, Inc. does not currently pay dividends.
Where can I find KZR SEC filings?
Official SEC filings for Kezar Life Sciences, Inc. (CIK: 0001645666) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KZR's EPS?
Kezar Life Sciences, Inc. has a diluted EPS of $-7.66.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KZR a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kezar Life Sciences, Inc. has a HOLD rating with 68% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KZR stock overvalued or undervalued?
Valuation metrics for KZR: ROE of -80.0% (sector avg: 15%), net margin of N/A (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KZR stock in 2026?
Our dual AI analysis gives Kezar Life Sciences, Inc. a combined HOLD rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KZR's free cash flow?
Kezar Life Sciences, Inc.'s operating cash flow is $-51.8M, with capital expenditures of $8.0K.
How does KZR compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin N/A (avg: 12%), ROE -80.0% (avg: 15%), current ratio 11.52 (avg: 2).